{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:37:50Z","timestamp":1792791470924,"version":"4.5.0"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T00:00:00Z","timestamp":1599609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T00:00:00Z","timestamp":1599609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Microbiol"],"DOI":"10.1038\/s41564-020-00789-5","type":"journal-article","created":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T07:26:39Z","timestamp":1599722799000},"page":"1185-1191","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":632,"title":["Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies"],"prefix":"10.1038","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7285-4054","authenticated-orcid":false,"given":"Wen Shi","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5593-9387","authenticated-orcid":false,"given":"Adam K.","family":"Wheatley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8539-4891","authenticated-orcid":false,"given":"Stephen J.","family":"Kent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6406-0836","authenticated-orcid":false,"given":"Brandon J.","family":"DeKosky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,9]]},"reference":[{"key":"789_CR1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41421-020-0153-3","volume":"6","author":"Y Zhou","year":"2020","unstructured":"Zhou, Y. et al. Network-based drug repurposing for novel coronavirus 2019-nCoV\/SARS-CoV-2. Cell Discov. 6, 14 (2020).","journal-title":"Cell Discov."},{"key":"789_CR2","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","volume":"395","author":"R Lu","year":"2020","unstructured":"Lu, R. et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395, 565\u2013574 (2020).","journal-title":"Lancet"},{"key":"789_CR3","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41586-020-2169-0","volume":"583","author":"TT Lam","year":"2020","unstructured":"Lam, T. T. et al. Identifying SARS-CoV-2 related coronaviruses in Malayan pangolins. Nature 583, 282\u2013285 (2020).","journal-title":"Nature"},{"key":"789_CR4","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271\u2013280 (2020).","journal-title":"Cell"},{"key":"789_CR5","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1126\/science.abb2762","volume":"367","author":"R Yan","year":"2020","unstructured":"Yan, R. et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 367, 1444\u20131448 (2020).","journal-title":"Science"},{"key":"789_CR6","unstructured":"Daly, J. L. et al. Neuropilin-1 is a host factor for SARS-CoV-2 infection. Preprint at https:\/\/www.biorxiv.org\/content\/10.1101\/2020.06.05.134114v1 (2020)."},{"key":"789_CR7","doi-asserted-by":"crossref","unstructured":"Cantuti-Castelvetri, L. et al. Neuropilin-1 facilitates SARS-CoV-2 cell entry and provides a possible pathway into the central nervous system. Preprint at https:\/\/www.biorxiv.org\/content\/10.1101\/2020.06.07.137802v1 (2020).","DOI":"10.1101\/2020.06.07.137802"},{"key":"789_CR8","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260\u20131263 (2020).","journal-title":"Science"},{"key":"789_CR9","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1093\/oxfordjournals.aje.a120955","volume":"89","author":"HW Kim","year":"1969","unstructured":"Kim, H. W. et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89, 422\u2013434 (1969).","journal-title":"Am. J. Epidemiol."},{"key":"789_CR10","doi-asserted-by":"publisher","first-page":"3535","DOI":"10.1016\/j.vaccine.2016.04.083","volume":"34","author":"BS Graham","year":"2016","unstructured":"Graham, B. S. Vaccines against respiratory syncytial virus: the time has finally come. Vaccine 34, 3535\u20133541 (2016).","journal-title":"Vaccine"},{"key":"789_CR11","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S0022-3476(68)80396-8","volume":"72","author":"PR Nader","year":"1968","unstructured":"Nader, P. R., Horwitz, M. S. & Rousseau, J. Atypical exanthem following exposure to natural measles: eleven cases in children previously inoculated with killed vaccine. J. Pediatr. 72, 22\u201328 (1968).","journal-title":"J. Pediatr."},{"key":"789_CR12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1203\/PDR.0b013e3180686ce0","volume":"62","author":"FP Polack","year":"2007","unstructured":"Polack, F. P. Atypical measles and enhanced respiratory syncytial virus disease (ERD) made simple. Pediatr. Res. 62, 111\u2013115 (2007).","journal-title":"Pediatr. Res."},{"key":"789_CR13","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1126\/science.1185181","volume":"328","author":"W Dejnirattisai","year":"2010","unstructured":"Dejnirattisai, W. et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science 328, 745\u2013748 (2010).","journal-title":"Science"},{"key":"789_CR14","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1056\/NEJMoa1800820","volume":"379","author":"S Sridhar","year":"2018","unstructured":"Sridhar, S. et al. Effect of dengue serostatus on dengue vaccine safety and efficacy. N. Engl. J. Med. 379, 327\u2013340 (2018).","journal-title":"N. Engl. J. Med."},{"key":"789_CR15","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1292\/jvms.60.49","volume":"60","author":"T Hohdatsu","year":"1998","unstructured":"Hohdatsu, T. et al. Antibody-dependent enhancement of feline infectious peritonitis virus infection in feline alveolar macrophages and human monocyte cell line U937 by serum of cats experimentally or naturally infected with feline coronavirus. J. Vet. Med. Sci. 60, 49\u201355 (1998).","journal-title":"J. Vet. Med. Sci."},{"key":"789_CR16","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1084\/jem.146.1.201","volume":"146","author":"SB Halstead","year":"1977","unstructured":"Halstead, S. B. & O\u2019Rourke, E. J. Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J. Exp. Med. 146, 201\u2013217 (1977).","journal-title":"J. Exp. Med."},{"key":"789_CR17","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1128\/jvi.64.3.1407-1409.1990","volume":"64","author":"H Vennema","year":"1990","unstructured":"Vennema, H. et al. Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization. J. Virol. 64, 1407\u20131409 (1990).","journal-title":"J. Virol."},{"key":"789_CR18","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/BF01310476","volume":"120","author":"T Hohdatsu","year":"1991","unstructured":"Hohdatsu, T., Nakamura, M., Ishizuka, Y., Yamada, H. & Koyama, H. A study on the mechanism of antibody-dependent enhancement of feline infectious peritonitis virus infection in feline macrophages by monoclonal antibodies. Arch. Virol. 120, 207\u2013217 (1991).","journal-title":"Arch. Virol."},{"key":"789_CR19","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/0147-9571(81)90003-5","volume":"4","author":"RC Weiss","year":"1981","unstructured":"Weiss, R. C. & Scott, F. W. Antibody-mediated enhancement of disease in feline infectious peritonitis: comparisons with dengue hemorrhagic fever. Comp. Immunol. Microbiol. Infect. Dis. 4, 175\u2013189 (1981).","journal-title":"Comp. Immunol. Microbiol. Infect. Dis."},{"key":"789_CR20","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3389\/fimmu.2017.00317","volume":"8","author":"ZW Ye","year":"2017","unstructured":"Ye, Z. W. et al. Antibody-dependent cell-mediated cytotoxicity epitopes on the hemagglutinin head region of pandemic H1N1 influenza virus play detrimental roles in H1N1-infected mice. Front. Immunol. 8, 317 (2017).","journal-title":"Front. Immunol."},{"key":"789_CR21","doi-asserted-by":"publisher","first-page":"15194","DOI":"10.1073\/pnas.1821317116","volume":"116","author":"KL Winarski","year":"2019","unstructured":"Winarski, K. L. et al. Antibody-dependent enhancement of influenza disease promoted by increase in hemagglutinin stem flexibility and virus fusion kinetics. Proc. Natl Acad. Sci. USA 116, 15194\u201315199 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"789_CR22","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1084\/jem.20020781","volume":"196","author":"FP Polack","year":"2002","unstructured":"Polack, F. P. et al. A role for immune complexes in enhanced respiratory syncytial virus disease. J. Exp. Med. 196, 859\u2013865 (2002).","journal-title":"J. Exp. Med."},{"key":"789_CR23","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1038\/nm918","volume":"9","author":"FP Polack","year":"2003","unstructured":"Polack, F. P., Hoffman, S. J., Crujeiras, G. & Griffin, D. E. A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles. Nat. Med. 9, 1209\u20131213 (2003).","journal-title":"Nat. Med."},{"key":"789_CR24","doi-asserted-by":"crossref","unstructured":"Gao, T. et al. Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation. Preprint at https:\/\/www.medrxiv.org\/content\/10.1101\/2020.03.29.20041962v3 (2020).","DOI":"10.1101\/2020.03.29.20041962"},{"key":"789_CR25","doi-asserted-by":"publisher","first-page":"e01753-18","DOI":"10.1128\/mBio.01753-18","volume":"9","author":"LE Gralinski","year":"2018","unstructured":"Gralinski, L. E. et al. Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis. mBio 9, e01753-18 (2018).","journal-title":"mBio"},{"key":"789_CR26","doi-asserted-by":"crossref","unstructured":"Larsen, M. D. et al. Afucosylated immunoglobulin G responses are a hallmark of enveloped virus infections and show an exacerbated phenotype in COVID-19. Preprint at https:\/\/www.biorxiv.org\/content\/10.1101\/2020.05.18.099507v1 (2020).","DOI":"10.1101\/2020.05.18.099507"},{"key":"789_CR27","unstructured":"Chakraborty, S. et al. Symptomatic SARS-CoV-2 infections display specific IgG Fc structures. Preprint at https:\/\/www.medrxiv.org\/content\/10.1101\/2020.05.15.20103341v1 (2020)."},{"key":"789_CR28","doi-asserted-by":"publisher","first-page":"5992","DOI":"10.1073\/pnas.1402458111","volume":"111","author":"A Hiatt","year":"2014","unstructured":"Hiatt, A. et al. Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy. Proc. Natl Acad. Sci. USA 111, 5992\u20135997 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"789_CR29","doi-asserted-by":"publisher","first-page":"20690","DOI":"10.1073\/pnas.1108360108","volume":"108","author":"L Zeitlin","year":"2011","unstructured":"Zeitlin, L. et al. Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant. Proc. Natl Acad. Sci. USA 108, 20690\u201320694 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"789_CR30","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1126\/science.aai8128","volume":"355","author":"TT Wang","year":"2017","unstructured":"Wang, T. T. et al. IgG antibodies to dengue enhanced for Fc\u03b3RIIIA binding determine disease severity. Science 355, 395\u2013398 (2017).","journal-title":"Science"},{"key":"789_CR31","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S2213-2600(20)30193-4","volume":"8","author":"KPY Hui","year":"2020","unstructured":"Hui, K. P. Y. et al. Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures. Lancet Respir. Med. 8, 687\u2013695 (2020).","journal-title":"Lancet Respir. Med."},{"key":"789_CR32","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/1743-422X-11-82","volume":"11","author":"MS Yip","year":"2014","unstructured":"Yip, M. S. et al. Antibody-dependent infection of human macrophages by severe acute respiratory syndrome coronavirus. Virol. J. 11, 82 (2014).","journal-title":"Virol. J."},{"key":"789_CR33","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/S0140-6736(88)91657-1","volume":"1","author":"WE Robinson Jr","year":"1988","unstructured":"Robinson, W. E. Jr, Montefiori, D. C. & Mitchell, W. M. Antibody-dependent enhancement of human immunodeficiency virus type 1 infection. Lancet 1, 790\u2013794 (1988).","journal-title":"Lancet"},{"key":"789_CR34","doi-asserted-by":"publisher","first-page":"4710","DOI":"10.1073\/pnas.86.12.4710","volume":"86","author":"WE Robinson Jr","year":"1989","unstructured":"Robinson, W. E. Jr et al. Antibody-dependent enhancement of human immunodeficiency virus type 1 (HIV-1) infection in vitro by serum from HIV-1-infected and passively immunized chimpanzees. Proc. Natl Acad. Sci. USA 86, 4710\u20134714 (1989).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"789_CR35","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1128\/JVI.75.5.2324-2330.2001","volume":"75","author":"A Takada","year":"2001","unstructured":"Takada, A., Watanabe, S., Okazaki, K., Kida, H. & Kawaoka, Y. Infectivity-enhancing antibodies to Ebola virus glycoprotein. J. Virol. 75, 2324\u20132330 (2001).","journal-title":"J. Virol."},{"key":"789_CR36","doi-asserted-by":"publisher","first-page":"7539","DOI":"10.1128\/JVI.77.13.7539-7544.2003","volume":"77","author":"A Takada","year":"2003","unstructured":"Takada, A., Feldmann, H., Ksiazek, T. G. & Kawaoka, Y. Antibody-dependent enhancement of Ebola virus infection. J. Virol. 77, 7539\u20137544 (2003).","journal-title":"J. Virol."},{"key":"789_CR37","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/jmv.1890360312","volume":"36","author":"H Ochiai","year":"1992","unstructured":"Ochiai, H. et al. Infection enhancement of influenza A NWS virus in primary murine macrophages by anti-hemagglutinin monoclonal antibody. J. Med. Virol. 36, 217\u2013221 (1992).","journal-title":"J. Med. Virol."},{"key":"789_CR38","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.tim.2017.10.004","volume":"26","author":"CA Sariol","year":"2018","unstructured":"Sariol, C. A., Nogueira, M. L. & Vasilakis, N. A tale of two viruses: does heterologous flavivirus immunity enhance Zika disease? Trends Microbiol. 26, 186\u2013190 (2018).","journal-title":"Trends Microbiol."},{"key":"789_CR39","doi-asserted-by":"publisher","first-page":"e02015-19","DOI":"10.1128\/JVI.02015-19","volume":"94","author":"Y Wan","year":"2020","unstructured":"Wan, Y. et al. Molecular mechanism for antibody-dependent enhancement of coronavirus entry. J. Virol. 94, e02015-19 (2020).","journal-title":"J. Virol."},{"key":"789_CR40","doi-asserted-by":"publisher","first-page":"10582","DOI":"10.1128\/JVI.00671-11","volume":"85","author":"M Jaume","year":"2011","unstructured":"Jaume, M. et al. Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH- and cysteine protease-independent Fc\u03b3R pathway. J. Virol. 85, 10582\u201310597 (2011).","journal-title":"J. Virol."},{"key":"789_CR41","doi-asserted-by":"publisher","first-page":"7819","DOI":"10.1128\/JVI.79.12.7819-7826.2005","volume":"79","author":"CY Cheung","year":"2005","unstructured":"Cheung, C. Y. et al. Cytokine responses in severe acute respiratory syndrome coronavirus-infected macrophages in vitro: possible relevance to pathogenesis. J. Virol. 79, 7819\u20137826 (2005).","journal-title":"J. Virol."},{"key":"789_CR42","first-page":"25","volume":"22","author":"MS Yip","year":"2016","unstructured":"Yip, M. S. et al. Antibody-dependent enhancement of SARS coronavirus infection and its role in the pathogenesis of SARS. Hong Kong Med. J. 22, 25\u201331 (2016).","journal-title":"Hong Kong Med. J."},{"key":"789_CR43","doi-asserted-by":"publisher","first-page":"e0154461","DOI":"10.1371\/journal.pone.0154461","volume":"11","author":"F Ana-Sosa-Batiz","year":"2016","unstructured":"Ana-Sosa-Batiz, F. et al. Influenza-specific antibody-dependent phagocytosis. PLoS ONE 11, e0154461 (2016).","journal-title":"PLoS ONE"},{"key":"789_CR44","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.virol.2014.02.005","volume":"454\u2013455","author":"F Yasui","year":"2014","unstructured":"Yasui, F. et al. Phagocytic cells contribute to the antibody-mediated elimination of pulmonary-infected SARS coronavirus. Virology 454\u2013455, 157\u2013168 (2014).","journal-title":"Virology"},{"key":"789_CR45","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1093\/infdis\/jit504","volume":"209","author":"J Zhou","year":"2014","unstructured":"Zhou, J. et al. Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis. J. Infect. Dis. 209, 1331\u20131342 (2014).","journal-title":"J. Infect. Dis."},{"key":"789_CR46","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.3201\/eid1111.040659","volume":"11","author":"MS Ho","year":"2005","unstructured":"Ho, M. S. et al. Neutralizing antibody response and SARS severity. Emerg. Infect. Dis. 11, 1730\u20131737 (2005).","journal-title":"Emerg. Infect. Dis."},{"key":"789_CR47","doi-asserted-by":"publisher","unstructured":"Zhao, J. et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciaa344 (2020).","DOI":"10.1093\/cid\/ciaa344"},{"key":"789_CR48","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/S1473-3099(20)30232-2","volume":"20","author":"Y Liu","year":"2020","unstructured":"Liu, Y. et al. Viral dynamics in mild and severe cases of COVID-19. Lancet Infect. Dis. 20, 656\u2013657 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"789_CR49","doi-asserted-by":"publisher","first-page":"m1443","DOI":"10.1136\/bmj.m1443","volume":"369","author":"S Zheng","year":"2020","unstructured":"Zheng, S. et al. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January\u2013March 2020: retrospective cohort study. BMJ 369, m1443 (2020).","journal-title":"BMJ"},{"key":"789_CR50","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/s41591-020-0965-6","volume":"26","author":"QX Long","year":"2020","unstructured":"Long, Q. X. et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat. Med. 26, 1200\u20131204 (2020).","journal-title":"Nat. Med."},{"key":"789_CR51","doi-asserted-by":"publisher","unstructured":"Sekine, T. et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell https:\/\/doi.org\/10.1016\/j.cell.2020.08.017 (2020).","DOI":"10.1016\/j.cell.2020.08.017"},{"key":"789_CR52","doi-asserted-by":"publisher","unstructured":"Mathew, D., Giles, J. R., Baxter, A. E., Oldridge, D. A. & Greenplate, A. R. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science https:\/\/doi.org\/10.1126\/science.abc8511 (2020).","DOI":"10.1126\/science.abc8511"},{"key":"789_CR53","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.micinf.2020.02.006","volume":"22","author":"JA Tetro","year":"2020","unstructured":"Tetro, J. A. Is COVID-19 receiving ADE from other coronaviruses? Microbes Infect. 22, 72\u201373 (2020).","journal-title":"Microbes Infect."},{"key":"789_CR54","doi-asserted-by":"crossref","unstructured":"Khan, S. et al. Analysis of serologic cross-reactivity between common human coronaviruses and SARS-CoV-2 using coronavirus antigen microarray. Preprint at https:\/\/www.biorxiv.org\/content\/10.1101\/2020.03.24.006544v1 (2020).","DOI":"10.1101\/2020.03.24.006544"},{"key":"789_CR55","doi-asserted-by":"publisher","first-page":"e35421","DOI":"10.1371\/journal.pone.0035421","volume":"7","author":"CT Tseng","year":"2012","unstructured":"Tseng, C. T. et al. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS ONE 7, e35421 (2012).","journal-title":"PLoS ONE"},{"key":"789_CR56","doi-asserted-by":"publisher","first-page":"e525","DOI":"10.1371\/journal.pmed.0030525","volume":"3","author":"D Deming","year":"2006","unstructured":"Deming, D. et al. Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants. PLoS Med. 3, e525 (2006).","journal-title":"PLoS Med."},{"key":"789_CR57","doi-asserted-by":"publisher","first-page":"12201","DOI":"10.1128\/JVI.06048-11","volume":"85","author":"M Bolles","year":"2011","unstructured":"Bolles, M. et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J. Virol. 85, 12201\u201312215 (2011).","journal-title":"J. Virol."},{"key":"789_CR58","doi-asserted-by":"publisher","first-page":"6337","DOI":"10.4049\/jimmunol.181.9.6337","volume":"181","author":"F Yasui","year":"2008","unstructured":"Yasui, F. et al. Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV. J. Immunol. 181, 6337\u20136348 (2008).","journal-title":"J. Immunol."},{"key":"789_CR59","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1080\/21645515.2016.1177688","volume":"12","author":"AS Agrawal","year":"2016","unstructured":"Agrawal, A. S. et al. Immunization with inactivated Middle East respiratory syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus. Hum. Vaccin. Immunother. 12, 2351\u20132356 (2016).","journal-title":"Hum. Vaccin. Immunother."},{"key":"789_CR60","doi-asserted-by":"publisher","first-page":"12672","DOI":"10.1128\/JVI.78.22.12672-12676.2004","volume":"78","author":"H Weingartl","year":"2004","unstructured":"Weingartl, H. et al. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J. Virol. 78, 12672\u201312676 (2004).","journal-title":"J. Virol."},{"key":"789_CR61","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1016\/j.vaccine.2005.01.033","volume":"23","author":"M Czub","year":"2005","unstructured":"Czub, M., Weingartl, H., Czub, S., He, R. & Cao, J. Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets. Vaccine 23, 2273\u20132279 (2005).","journal-title":"Vaccine"},{"key":"789_CR62","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1128\/JVI.02980-14","volume":"89","author":"Y Honda-Okubo","year":"2015","unstructured":"Honda-Okubo, Y. et al. Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology. J. Virol. 89, 2995\u20133007 (2015).","journal-title":"J. Virol."},{"key":"789_CR63","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1093\/infdis\/jiz137","volume":"220","author":"AM Hashem","year":"2019","unstructured":"Hashem, A. M. et al. A highly immunogenic, protective, and safe adenovirus-based vaccine expressing Middle East respiratory syndrome coronavirus S1-CD40L fusion protein in a transgenic human dipeptidyl peptidase 4 mouse model. J. Infect. Dis. 220, 1558\u20131567 (2019).","journal-title":"J. Infect. Dis."},{"key":"789_CR64","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1126\/science.abc1731","volume":"368","author":"AJ London","year":"2020","unstructured":"London, A. J. & Kimmelman, J. Against pandemic research exceptionalism. Science 368, 476\u2013477 (2020).","journal-title":"Science"},{"key":"789_CR65","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1056\/NEJMp2005630","volume":"382","author":"N Lurie","year":"2020","unstructured":"Lurie, N., Saville, M., Hatchett, R. & Halton, J. Developing Covid-19 vaccines at pandemic speed. N. Engl. J. Med. 382, 1969\u20131973 (2020).","journal-title":"N. Engl. J. Med."},{"key":"789_CR66","doi-asserted-by":"publisher","first-page":"e123158","DOI":"10.1172\/jci.insight.123158","volume":"4","author":"L Liu","year":"2019","unstructured":"Liu, L. et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight 4, e123158 (2019).","journal-title":"JCI Insight"},{"key":"789_CR67","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1021\/acsinfecdis.6b00006","volume":"2","author":"Q Wang","year":"2016","unstructured":"Wang, Q. et al. Immunodominant SARS coronavirus epitopes in humans elicited both enhancing and neutralizing effects on infection in non-human primates. ACS Infect. Dis. 2, 361\u2013376 (2016).","journal-title":"ACS Infect. Dis."},{"key":"789_CR68","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s12250-018-0009-2","volume":"33","author":"F Luo","year":"2018","unstructured":"Luo, F. et al. Evaluation of antibody-dependent enhancement of SARS-CoV infection in rhesus macaques immunized with an inactivated SARS-CoV vaccine. Virol. Sin. 33, 201\u2013204 (2018).","journal-title":"Virol. Sin."},{"key":"789_CR69","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.vaccine.2005.06.038","volume":"24","author":"E Qin","year":"2006","unstructured":"Qin, E. et al. Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine. Vaccine 24, 1028\u20131034 (2006).","journal-title":"Vaccine"},{"key":"789_CR70","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.vaccine.2006.08.011","volume":"25","author":"YW Kam","year":"2007","unstructured":"Kam, Y. W. et al. Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate Fc\u03b3RII-dependent entry into B cells in vitro. Vaccine 25, 729\u2013740 (2007).","journal-title":"Vaccine"},{"key":"789_CR71","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nature02463","volume":"428","author":"ZY Yang","year":"2004","unstructured":"Yang, Z. Y. et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 428, 561\u2013564 (2004).","journal-title":"Nature"},{"key":"789_CR72","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1016\/S0140-6736(04)16501-X","volume":"363","author":"A Bukreyev","year":"2004","unstructured":"Bukreyev, A. et al. Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet 363, 2122\u20132127 (2004).","journal-title":"Lancet"},{"key":"789_CR73","doi-asserted-by":"publisher","first-page":"6641","DOI":"10.1073\/pnas.0401939101","volume":"101","author":"H Bisht","year":"2004","unstructured":"Bisht, H. et al. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc. Natl Acad. Sci. USA 101, 6641\u20136646 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"789_CR74","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1126\/science.abc1932","volume":"369","author":"Q Gao","year":"2020","unstructured":"Gao, Q. et al. Rapid development of an inactivated vaccine candidate for SARS-CoV-2. Science 369, 77\u201381 (2020).","journal-title":"Science"},{"key":"789_CR75","doi-asserted-by":"publisher","unstructured":"Chan, J. F. et al. Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciaa325 (2020).","DOI":"10.1093\/cid\/ciaa325"},{"key":"789_CR76","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41586-020-2380-z","volume":"584","author":"B Ju","year":"2020","unstructured":"Ju, B. et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature 584, 115\u2013119 (2020).","journal-title":"Nature"},{"key":"789_CR77","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1126\/science.abc5902","volume":"369","author":"PJM Brouwer","year":"2020","unstructured":"Brouwer, P. J. M. et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science 369, 643\u2013650 (2020).","journal-title":"Science"},{"key":"789_CR78","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1126\/science.abd0827","volume":"369","author":"J Hansen","year":"2020","unstructured":"Hansen, J. et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science 369, 1010\u20131014 (2020).","journal-title":"Science"},{"key":"789_CR79","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1126\/science.abb7269","volume":"368","author":"M Yuan","year":"2020","unstructured":"Yuan, M. et al. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science 368, 630\u2013633 (2020).","journal-title":"Science"},{"key":"789_CR80","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41586-020-2381-y","volume":"584","author":"R Shi","year":"2020","unstructured":"Shi, R. et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature 584, 120\u2013124 (2020).","journal-title":"Nature"},{"key":"789_CR81","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.cell.2020.05.025","volume":"182","author":"Y Cao","year":"2020","unstructured":"Cao, Y. et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients\u2019 B cells. Cell 182, 73\u201384 (2020).","journal-title":"Cell"},{"key":"789_CR82","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1126\/science.abc7520","volume":"369","author":"TF Rogers","year":"2020","unstructured":"Rogers, T. F. et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science 369, 956\u2013963 (2020).","journal-title":"Science"},{"key":"789_CR83","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S0065-3527(03)60011-4","volume":"60","author":"SB Halstead","year":"2003","unstructured":"Halstead, S. B. Neutralization and antibody-dependent enhancement of dengue viruses. Adv. Virus. Res. 60, 421\u2013467 (2003).","journal-title":"Adv. Virus. Res."},{"key":"789_CR84","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1172\/JCI84428","volume":"126","author":"DJ DiLillo","year":"2016","unstructured":"DiLillo, D. J., Palese, P., Wilson, P. C. & Ravetch, J. V. Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection. J. Clin. Invest. 126, 605\u2013610 (2016).","journal-title":"J. Clin. Invest."},{"key":"789_CR85","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-08165-y","volume":"10","author":"Y Liu","year":"2019","unstructured":"Liu, Y. et al. Cross-lineage protection by human antibodies binding the influenza B hemagglutinin. Nat. Commun. 10, 324 (2019).","journal-title":"Nat. Commun."},{"key":"789_CR86","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nature06106","volume":"449","author":"AJ Hessell","year":"2007","unstructured":"Hessell, A. J. et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449, 101\u2013104 (2007).","journal-title":"Nature"},{"key":"789_CR87","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1172\/JCI122466","volume":"129","author":"MS Parsons","year":"2019","unstructured":"Parsons, M. S. et al. Fc-dependent functions are redundant to efficacy of anti-HIV antibody PGT121 in macaques. J. Clin. Invest. 129, 182\u2013191 (2019).","journal-title":"J. Clin. Invest."},{"key":"789_CR88","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3389\/fimmu.2019.00697","volume":"10","author":"AR Crowley","year":"2019","unstructured":"Crowley, A. R. & Ackerman, M. E. Mind the gap: how interspecies variability in IgG and its receptors may complicate comparisons of human and non-human primate effector function. Front. Immunol. 10, 69 (2019).","journal-title":"Front. Immunol."},{"key":"789_CR89","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/infdis\/jiu396","volume":"211","author":"J Mair-Jenkins","year":"2015","unstructured":"Mair-Jenkins, J. et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J. Infect. Dis. 211, 80\u201390 (2015).","journal-title":"J. Infect. Dis."},{"key":"789_CR90","doi-asserted-by":"publisher","first-page":"617","DOI":"10.3851\/IMP3243","volume":"23","author":"JH Ko","year":"2018","unstructured":"Ko, J. H. et al. Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience. Antivir. Ther. 23, 617\u2013622 (2018).","journal-title":"Antivir. Ther."},{"key":"789_CR91","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s10096-004-1271-9","volume":"24","author":"Y Cheng","year":"2005","unstructured":"Cheng, Y. et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur. J. Clin. Microbiol. Infect. Dis. 24, 44\u201346 (2005).","journal-title":"J. Clin. Microbiol. Infect. Dis."},{"key":"789_CR92","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1001\/jama.2020.4783","volume":"323","author":"C Shen","year":"2020","unstructured":"Shen, C. et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA 323, 1582\u20131589 (2020).","journal-title":"JAMA"},{"key":"789_CR93","doi-asserted-by":"publisher","first-page":"9490","DOI":"10.1073\/pnas.2004168117","volume":"117","author":"K Duan","year":"2020","unstructured":"Duan, K. et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc. Natl Acad. Sci. USA 117, 9490\u20139496 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"789_CR94","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.3346\/jkms.2020.35.e149","volume":"35","author":"JY Ahn","year":"2020","unstructured":"Ahn, J. Y. et al. Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea. J. Korean Med. Sci. 35, e149 (2020).","journal-title":"J. Korean Med. Sci."},{"key":"789_CR95","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1016\/j.chest.2020.03.039","volume":"158","author":"B Zhang","year":"2020","unstructured":"Zhang, B. et al. Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection. Chest 158, e9\u2013e13 (2020).","journal-title":"Chest"},{"key":"789_CR96","doi-asserted-by":"publisher","unstructured":"Joyner, M. J. et al. Early safety indicators of COVID-19 convalescent plasma in 5,000 patients. J. Clin. Invest. https:\/\/doi.org\/10.1172\/JCI140200 (2020).","DOI":"10.1172\/JCI140200"},{"key":"789_CR97","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1001\/jama.2020.10044","volume":"324","author":"L Li","year":"2020","unstructured":"Li, L. et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA 324, 460\u2013470 (2020).","journal-title":"JAMA"},{"key":"789_CR98","unstructured":"Gharbharan, A. et al. Convalescent plasma for COVID-19. A randomized clinical trial. Preprint at https:\/\/www.medrxiv.org\/content\/10.1101\/2020.07.01.20139857v1 (2020)."},{"key":"789_CR99","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1172\/JCI138003","volume":"130","author":"A Casadevall","year":"2020","unstructured":"Casadevall, A. & Pirofski, L. A. The convalescent sera option for containing COVID-19. J. Clin. Invest. 130, 1545\u20131548 (2020).","journal-title":"J. Clin. Invest."},{"issue":"Suppl. 1","key":"789_CR100","doi-asserted-by":"publisher","first-page":"65S","DOI":"10.1111\/j.1537-2995.2012.03663.x","volume":"52","author":"S Pandey","year":"2012","unstructured":"Pandey, S. & Vyas, G. N. Adverse effects of plasma transfusion. Transfusion 52 (Suppl. 1), 65S\u201379S (2012).","journal-title":"Transfusion"}],"container-title":["Nature Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41564-020-00789-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41564-020-00789-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41564-020-00789-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T22:54:32Z","timestamp":1670280872000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41564-020-00789-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,9]]},"references-count":100,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,10]]}},"alternative-id":["789"],"URL":"https:\/\/doi.org\/10.1038\/s41564-020-00789-5","relation":{},"ISSN":["2058-5276"],"issn-type":[{"value":"2058-5276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,9]]},"assertion":[{"value":"16 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}